Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
WebcastCPE Webcast: Taking a data-first, questionnaire-second approach to TPRM
Join us for a live webcast to learn how the newest risk exchange models are eliminating 80 percent of questionnaire requests with data.
-
WebcastApr. 22 | Slow Vendors, Changing Risks: The Compliance Customization Gap
A recent survey found that 66% of compliance leaders say their training programs are hard to customize quickly, and nearly half (46%) are being asked to cut training time.